Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.

Matthew W. Sherwood, Stephen D. Wiviott, S. Andrew Peng, Matthew T. Roe, James A de Lemos, Eric D. Peterson, Tracy Y. Wang

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

P2Y12 antagonist therapy improves outcomes in acute myocardial infarction (MI) patients. Novel agents in this class are now available in the US. We studied the introduction of prasugrel into contemporary MI practice to understand the appropriateness of its use and assess for changes in antiplatelet management practices. Using ACTION Registry-GWTG (Get-with-the-Guidelines), we evaluated patterns of P2Y12 antagonist use within 24 hours of admission in 100 228 ST elevation myocardial infarction (STEMI) and 158 492 Non-ST elevation myocardial infarction (NSTEMI) patients at 548 hospitals between October 2009 and September 2012. Rates of early P2Y12 antagonist use were approximately 90% among STEMI and 57% among NSTEMI patients. From 2009 to 2012, prasugrel use increased significantly from 3% to 18% (5% to 30% in STEMI; 2% to 10% in NSTEMI; P for trend <0.001 for all). During the same period, we observed a decrease in use of early but not discharge P2Y12 antagonist among NSTEMI patients. Although contraindicated, 3.0% of patients with prior stroke received prasugrel. Prasugrel was used in 1.9% of patients ≥75 years and 4.5% of patients with weight <60 kg. In both STEMI and NSTEMI, prasugrel was most frequently used in patients at the lowest predicted risk for bleeding and mortality. Despite lack of supporting evidence, prasugrel was initiated before cardiac catheterization in 18% of NSTEMI patients. With prasugrel as an antiplatelet treatment option, contemporary practice shows low uptake of prasugrel and delays in P2Y12 antagonist initiation among NSTEMI patients. We also note concerning evidence of inappropriate use of prasugrel, and inadequate targeting of this more potent therapy to maximize the benefit/risk ratio.

Original languageEnglish (US)
JournalJournal of the American Heart Association
Volume3
Issue number2
DOIs
StatePublished - 2014

Fingerprint

clopidogrel
Registries
Myocardial Infarction
Non-ST Elevated Myocardial Infarction
ST Elevation Myocardial Infarction
Prasugrel Hydrochloride

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US : insights from the National Cardiovascular Data Registry. / Sherwood, Matthew W.; Wiviott, Stephen D.; Peng, S. Andrew; Roe, Matthew T.; de Lemos, James A; Peterson, Eric D.; Wang, Tracy Y.

In: Journal of the American Heart Association, Vol. 3, No. 2, 2014.

Research output: Contribution to journalArticle

Sherwood, Matthew W. ; Wiviott, Stephen D. ; Peng, S. Andrew ; Roe, Matthew T. ; de Lemos, James A ; Peterson, Eric D. ; Wang, Tracy Y. / Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US : insights from the National Cardiovascular Data Registry. In: Journal of the American Heart Association. 2014 ; Vol. 3, No. 2.
@article{90cbafbb52d14359a1f0ae5a8b276a91,
title = "Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.",
abstract = "P2Y12 antagonist therapy improves outcomes in acute myocardial infarction (MI) patients. Novel agents in this class are now available in the US. We studied the introduction of prasugrel into contemporary MI practice to understand the appropriateness of its use and assess for changes in antiplatelet management practices. Using ACTION Registry-GWTG (Get-with-the-Guidelines), we evaluated patterns of P2Y12 antagonist use within 24 hours of admission in 100 228 ST elevation myocardial infarction (STEMI) and 158 492 Non-ST elevation myocardial infarction (NSTEMI) patients at 548 hospitals between October 2009 and September 2012. Rates of early P2Y12 antagonist use were approximately 90{\%} among STEMI and 57{\%} among NSTEMI patients. From 2009 to 2012, prasugrel use increased significantly from 3{\%} to 18{\%} (5{\%} to 30{\%} in STEMI; 2{\%} to 10{\%} in NSTEMI; P for trend <0.001 for all). During the same period, we observed a decrease in use of early but not discharge P2Y12 antagonist among NSTEMI patients. Although contraindicated, 3.0{\%} of patients with prior stroke received prasugrel. Prasugrel was used in 1.9{\%} of patients ≥75 years and 4.5{\%} of patients with weight <60 kg. In both STEMI and NSTEMI, prasugrel was most frequently used in patients at the lowest predicted risk for bleeding and mortality. Despite lack of supporting evidence, prasugrel was initiated before cardiac catheterization in 18{\%} of NSTEMI patients. With prasugrel as an antiplatelet treatment option, contemporary practice shows low uptake of prasugrel and delays in P2Y12 antagonist initiation among NSTEMI patients. We also note concerning evidence of inappropriate use of prasugrel, and inadequate targeting of this more potent therapy to maximize the benefit/risk ratio.",
author = "Sherwood, {Matthew W.} and Wiviott, {Stephen D.} and Peng, {S. Andrew} and Roe, {Matthew T.} and {de Lemos}, {James A} and Peterson, {Eric D.} and Wang, {Tracy Y.}",
year = "2014",
doi = "10.1161/JAHA.114.000849",
language = "English (US)",
volume = "3",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US

T2 - insights from the National Cardiovascular Data Registry.

AU - Sherwood, Matthew W.

AU - Wiviott, Stephen D.

AU - Peng, S. Andrew

AU - Roe, Matthew T.

AU - de Lemos, James A

AU - Peterson, Eric D.

AU - Wang, Tracy Y.

PY - 2014

Y1 - 2014

N2 - P2Y12 antagonist therapy improves outcomes in acute myocardial infarction (MI) patients. Novel agents in this class are now available in the US. We studied the introduction of prasugrel into contemporary MI practice to understand the appropriateness of its use and assess for changes in antiplatelet management practices. Using ACTION Registry-GWTG (Get-with-the-Guidelines), we evaluated patterns of P2Y12 antagonist use within 24 hours of admission in 100 228 ST elevation myocardial infarction (STEMI) and 158 492 Non-ST elevation myocardial infarction (NSTEMI) patients at 548 hospitals between October 2009 and September 2012. Rates of early P2Y12 antagonist use were approximately 90% among STEMI and 57% among NSTEMI patients. From 2009 to 2012, prasugrel use increased significantly from 3% to 18% (5% to 30% in STEMI; 2% to 10% in NSTEMI; P for trend <0.001 for all). During the same period, we observed a decrease in use of early but not discharge P2Y12 antagonist among NSTEMI patients. Although contraindicated, 3.0% of patients with prior stroke received prasugrel. Prasugrel was used in 1.9% of patients ≥75 years and 4.5% of patients with weight <60 kg. In both STEMI and NSTEMI, prasugrel was most frequently used in patients at the lowest predicted risk for bleeding and mortality. Despite lack of supporting evidence, prasugrel was initiated before cardiac catheterization in 18% of NSTEMI patients. With prasugrel as an antiplatelet treatment option, contemporary practice shows low uptake of prasugrel and delays in P2Y12 antagonist initiation among NSTEMI patients. We also note concerning evidence of inappropriate use of prasugrel, and inadequate targeting of this more potent therapy to maximize the benefit/risk ratio.

AB - P2Y12 antagonist therapy improves outcomes in acute myocardial infarction (MI) patients. Novel agents in this class are now available in the US. We studied the introduction of prasugrel into contemporary MI practice to understand the appropriateness of its use and assess for changes in antiplatelet management practices. Using ACTION Registry-GWTG (Get-with-the-Guidelines), we evaluated patterns of P2Y12 antagonist use within 24 hours of admission in 100 228 ST elevation myocardial infarction (STEMI) and 158 492 Non-ST elevation myocardial infarction (NSTEMI) patients at 548 hospitals between October 2009 and September 2012. Rates of early P2Y12 antagonist use were approximately 90% among STEMI and 57% among NSTEMI patients. From 2009 to 2012, prasugrel use increased significantly from 3% to 18% (5% to 30% in STEMI; 2% to 10% in NSTEMI; P for trend <0.001 for all). During the same period, we observed a decrease in use of early but not discharge P2Y12 antagonist among NSTEMI patients. Although contraindicated, 3.0% of patients with prior stroke received prasugrel. Prasugrel was used in 1.9% of patients ≥75 years and 4.5% of patients with weight <60 kg. In both STEMI and NSTEMI, prasugrel was most frequently used in patients at the lowest predicted risk for bleeding and mortality. Despite lack of supporting evidence, prasugrel was initiated before cardiac catheterization in 18% of NSTEMI patients. With prasugrel as an antiplatelet treatment option, contemporary practice shows low uptake of prasugrel and delays in P2Y12 antagonist initiation among NSTEMI patients. We also note concerning evidence of inappropriate use of prasugrel, and inadequate targeting of this more potent therapy to maximize the benefit/risk ratio.

UR - http://www.scopus.com/inward/record.url?scp=84904621739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904621739&partnerID=8YFLogxK

U2 - 10.1161/JAHA.114.000849

DO - 10.1161/JAHA.114.000849

M3 - Article

C2 - 24732921

AN - SCOPUS:84904621739

VL - 3

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 2

ER -